A blood test being studied to find cancer early, including brain cancer
Original title: cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase was given for this study, so it is still an early test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study checks if a blood test can spot cancer, and spot it coming back.
Who this trial is for. This study includes people with cancer and people without it. Brain cancer is one of the cancers being looked at. It tests a blood test that reads DNA for signs of cancer.
Where it stands. The team wants to know if the test can find cancer. They also want to know if it can tell one kind of cancer from another. In lung cancer, they are checking if the test can find cancer left after treatment ends. They are also checking if it can spot cancer coming back before a person feels sick. The study has not reported results.
What this means, and what it doesn't
What it could mean: A blood test like this could one day help find cancer sooner. That is not known yet. This study does not treat a tumor. It collects information. Someone who fits might ask their care team about it.
What it doesn't mean: This does not mean the blood test works. A trial is a test, not proven care. Joining one is not a promise that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, November 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.